首页 课程 直播 学堂
登录|注册

距开始播出还有

小时

强大生物科技加速,精准医学提前到来

直播日期 2021/01/22 14:00

我要报名 进入直播观看

请先点击“我要报名”进行报名,直播开始前半小时,点击“进入直播观看”填写报名时的邮箱及手机号即可进入直播。

强大生物科技加速,精准医学提前到来

体内生物学的深入了解对于医学未来的发展兹事体大,尤其是对疾病产生持久的治疗效果的方面。本次活动将透过各种数据和真实案例,与您分享IsoPlexis独特的单细胞蛋白质技术应用,从中研究人员能学习到如何首次将蛋白质组学与单细胞生物学相结合来加速治疗药物的发展。

The future of advanced medicines relies upon deeper access to in vivo biology to create durable, curative impacts on disease. This event will take you through your journey discussing case studies and IsoPlexis' technology that enables researchers to merge dynamic proteomics and single cell biology for the first time to accelerate curative medicines.

单细胞细胞内蛋白质组解决方案:http://ypxcx.medsci.cn/IsoPlexis/index.html#/home

中国代理商:杭州纽蓝科技有限公司
地址:杭州市余杭区良渚街道金昌路2073号3号楼5楼
电话:0571-86800217
网址:www.nl17.com
联系人:俞经理,yuping@nl17.com
联系方式:+86-13067839969


会议日程

时间 主题 讲师
14:00-15:00 Shifting time and Space: How harnessing our most powerful cells is changing immune medicine

Sean Mackay
Dr Rong Fan
Dr James Heath
Jon Chen, MS

15:00-16:00 The Role of Single-Cell Functional Biomarkers in Next-Generation Cancer Therapies

Dr Giulia Parisi
Jon Chen, MS
16:00-17:00 Improving COVID-19 Treatment & Vaccine Development

Dr Stacey Willard

嘉宾简介

Rong Fan博士(IsoPlexis联合创始人与技术联合发明人、耶鲁大学工程与应用科学生物医学工程学院)

范荣博士的研究重点是开发和部署单细胞和空间多组学分析技术,这些技术通常基于微制造装置,以研究复杂人类疾病(包括癌症、自身免疫和心血管疾病)的发病机制和治疗反应。特别是,他的实验室对血液恶性肿瘤、脑肿瘤和系统性红斑狼疮感兴趣。他还对细胞免疫功能特性和癌症免疫疗法的应用感兴趣。

他的实验室开发的一种微芯片技术,用于同时测量单细胞中的42种免疫效应蛋白,该蛋白目前仍是单细胞蛋白质分泌测定的最高多路复用技术,现已商业化为IsoCode和IsoLight,目前在美国和世界各地的数十个综合性癌症中心和制药公司使用。

最近,他的实验室正在开发高空间分辨率多组位测序技术,该技术可能在发育生物学、癌症研究、神经科学和免疫生物学领域得到广泛的应用。

Professor of Biomedical Engineering School of Engineering and Applied Science, Yale University, IsoPlexis Co-Founder & Technology Co-Inventor.

Dr. Fan's research is focused on the development and deployment of single-cell and spatial multi-omics profiling technologies, often based on microfabricated devices, to investigate pathogenesis and therapeutic response of complex human diseases including cancer, autoimmunity, and cardiovascular disease. In particular, his laboratory is interested in hematologic malignancies, brain tumors, and systemic lupus erythematosus. He is also interested in cellular immune function characterization and the application to cancer immunotherapies.

A microchip technology his laboratory developed for simultaneous measurement of 42 immune effector proteins in single cells, which remains the highest multiplexing to date for a single-cell protein secretion assay, has been commercialized as IsoCode and IsoLight, and currently used by tens of comprehensive cancer centers and pharmaceutical companies in the U.S. and around the world.

Recently, his laboratory is working to develop high-spatial-resolution multi-omics sequencing technology, which may find wide-spread applications in developmental biology, cancer research, neuroscience, and immunobiology.

James R. Heath博士、联合主任(西雅图系统生物学研究所)

Heath 博士自2005年以来一直领导国家癌症研究所资助的NSB癌症中心。此前,他是加州理工学院的伊丽莎白·吉隆化学教授,并在2017年之前担任加州大学洛杉矶分校帕克癌症免疫治疗研究所的联合主任,他曾获得多项奖项和荣誉,包括美国癌症研究人员协会的欧文·温斯坦奖和萨克勒物理科学奖。

他被《福布斯》杂志评为世界七大创新者之一。希思创立或共同创立了多家公司,包括 PACT 制药、综合诊断、Indi 分子、CTI 分子成像(2005 年由西门子收购)、索菲生物科学、Isoplexis 和 NanoSys。

Dr. James R. Heath is President and Professor at Institute for Systems Biology in Seattle. Heath also has the position of Professor of Molecular and Medical Pharmacology at UCLA, and he has directed the National Cancer Institute-funded NSB Cancer Center since 2005. Formerly, he was the Elizabeth W. Gilloon Professor of Chemistry at Caltech, and served as co-director of the Parker Institute for Cancer Immunotherapy at UCLA until 2017.He has received several awards and honors, including the Irving Weinstein Award from the American Association of Cancer Researchers, and the Sackler Prize in the Physical Sciences.

He was named one of the top seven innovators in the world by Forbes Magazine. Heath has founded or cofounded several companies, including PACT Pharma, Integrated Diagnostics, Indi Molecular, CTI Molecular Imaging (acquired by Siemens in 2005), Sofie Biosciences, Isoplexis, and NanoSys.

Giulia Parisi博士(加州大学)

朱利亚.帕里西博士(Dr. Giulia Parisi )是加州大学,洛杉矶分校的项目科学家,拥有癌症研究、免疫治疗和表观遗传学方面的背景。她目前是唐纳德·科恩博士实验室的刀状细胞疾病临床试验的项目经理,专注于细胞基因治疗研究。

她还参与了临床前的研究,以开发一种改善急性骨髓性白血病的治疗。在基因治疗领域工作之前,她是加州大学洛杉矶分校医学、血液学和肿瘤学系安东尼·里巴斯博士实验室的博士后研究员。

自2013年加入以来,她的研究一直专注于寻找新的免疫疗法方法。特别是,她探索了在采用细胞疗法(ACT)的动物模型中使用白细胞间2的改性版本,以获得更好的毒性肿瘤反应的可能性。她在乌迪内大学获得临床科学与技技术博士学位。

Giulia Parisi, PhD, is a Project Scientist at UCLA, with a background in cancer research, immunotherapy, and epigenetics. She is currently the project manager of a sickle cell disease clinical trial in Dr. Donald B. Kohn’s lab, focused on cellular gene therapy research.

She is also involved in a pre-clinical study to develop an improved therapeutic for acute myeloid leukemia. Prior to working in the gene therapy field, she was a postdoctoral fellow in Dr. Antoni Ribas’ lab in the Department of Medicine, Hematology and Oncology at UCLA.

Since joining in 2013, her research has focused on finding new immunotherapy approaches. In particular, she has explored the possibility of using modified versions of interleukin 2 in an animal model of adoptive cell therapy (ACT) to obtain better tumor response with lower toxicity. She obtained her PhD in Clinical Sciences and Technologies at the University of Udine

Stacey Willard博士(IsoPlexis 产品管理总监)

Stacey在弗吉尼亚大学约与翰霍普金斯医学院获得奖学金并完成了她的博士学位。在加入产品为中心的角色之前,Stacey曾经进行多年的细胞生物学和肿瘤学研究工作,为研究人员带来了各种丰富的学术和行业经验。

Stacey received her PhD at the University of Virginia and completed a fellowship at Johns Hopkins Medical School. She brings rich experience in academia & industry having worked in cell biology & oncology research before transitioning into product-focused roles.

Jon Chen技术共同发明者(IsoPlexis)

Jon是 IsoPlexis 技术的共同发明者。Jon 在耶鲁大学的研究生工作探索了肿瘤微环境以及单细胞的免疫功能。他在加州大学圣地亚哥分校获得了生理学和神经科学学士学位,并学习视觉艺术。Jon 在肿瘤学和免疫调解疾病的界面上发表了多篇同行评议的文章。

Jon is the co-inventor of the IsoPlexis technology. Jon’s graduate work at Yale explores the tumor microenvironment and the immune function of single cells. He received his BS in Physiology and Neuroscience with a minor in visual arts at UC San Diego. Jon has published multiple peer-reviewed articles at the interface of oncology and immune mediated diseases.

Sean Mackay首席执行官(IsoPlexis 联合创始人)

IsoPlexis 的使命是提供广泛可可用的细胞蛋白质组学科技,以加快个性化的治疗药物速度。

该公司专注于将细胞和基因治疗、癌症免疫学和传染病的范式发展患者特定、更持久的治疗。IsoPlexis 易于使用的仪器和软件赢得了众多奖项,并在全球范围内用于推进精准医学。

此前,Sean 帮助孵育克莱纳·珀金斯支持的 Lifesquare,该广场通过共享基本医疗保健信息将患者、付款方和提供商连接起来。此外,通过在拉扎德的工作和几个早期创业,他发展出帮助生命科学和医疗设备公司在战略变革时期进行管理的热情,向临床生态系统提供他们急需的产品。

Sean 共同撰写了许多以免疫药物为中心的出版物,并在全球拥有多项单细胞产品的专利。

Sean Mackay co-founded and leads IsoPlexis as CEO. IsoPlexis’mission is to provide widely accessible cellular proteomics to speed personalized, curative medicines. The company focuses on shifting paradigms incell and gene therapy, cancer immunology, and infectious disease towards more patient specific, long lasting treatments. IsoPlexis’ easy to use instrumentation and software have won numerous awards and are used globally to advance precision medicine.

Previously, Sean helped incubate Kleiner Perkins-backed Lifesquare, which connected patients, payers, and providers through sharing essential healthcare information. Additionally, through work at Lazard and with several early-stage ventures, he developed a passion for helping life sciences and medical device companies manage in times of strategic change, to deliver their highly needed products to the clinical ecosystem. Sean has co-authored a number of publications centered around immune medicines and holds patents for a number of single-cell products worldwide.

其他讲堂

分享到微信朋友圈×